Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-29
DOI
10.1038/s41375-018-0265-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
- (2018) Hagop Kantarjian et al. LANCET ONCOLOGY
- Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study
- (2018) Weili Sun et al. LEUKEMIA
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- (2018) Elias Jabbour et al. JAMA Oncology
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
- (2017) Hagop M Kantarjian et al. Lancet Haematology
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia
- (2016) Weili Sun et al. PEDIATRIC BLOOD & CANCER
- Characterization of CD22 expression in acute lymphoblastic leukemia
- (2015) Nirali N. Shah et al. PEDIATRIC BLOOD & CANCER
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Relapsed childhood acute lymphoblastic leukaemia
- (2013) Deepa Bhojwani et al. LANCET ONCOLOGY
- Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
- (2013) Michael Rytting et al. PEDIATRIC BLOOD & CANCER
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
- (2011) N. Hijiya et al. BLOOD
- Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study
- (2009) Christian M. Zwaan et al. BRITISH JOURNAL OF HAEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation